EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models

Koji Nakamura iD, Kota Takahashi, Izumi Sakaguchi, Takumi Satoh, Lingyi Zhang, Hiroyuki Yanai, Yukihito Tsukumo

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252413627 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Koji Nakamura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chiome Bioscience Inc., 3-12-1 Honmachi, Shibuya-ku, Tokyo 151-0071, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Calcium-Binding Proteins, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Delta-like 1 homolog (DLK1), a non-canonical Notch ligand, is highly expressed in various malignant tumors, especially in hepatocellular carcinoma (HCC). CBA-1205 is an afucosylated humanized antibody against DLK1 with enhanced antibody-dependent cellular cytotoxicity (ADCC). The binding characteristics of CBA-1205 were analyzed by enzyme-linked immunosorbent assay and fluorescence-activated cell sorting assay. The ADCC activity of CBA-1205 was assessed. The anti-tumor efficacy of CBA-1205 was evaluated in xenograft mouse models, and toxicity and toxicokinetic profiles of CBA-1205 were evaluated in cynomolgus monkeys. CBA-1205 selectively bound to DLK1 among the Notch ligands and only to monkey and human DLK1. The binding epitope was between epidermal growth factor-like domains 1 and 2 of DLK1, which are not involved in any known physiological functions. The ADCC activity of CBA-1205 was confirmed using human peripheral blood mononuclear cells as effector cells. CBA-1205 as a single agent and in combination with lenvatinib demonstrated long-lasting anti-tumor efficacy, including tumor regression, in two liver cancer xenograft models. The toxicity and toxicokinetic profiles of CBA-1205 in cynomolgus monkeys were favorable. These findings suggest that CBA-1205 has the potential to be a useful therapeutic option for drug treatment in HCC. A phase 1 study is ongoing in patients with advanced cancers (jRCT2080225288, NCT06636435).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCalcium-Binding ProteinsCarcinoma, HepatocellularLiver NeoplasmsAnimalsHumansMiceAntibody-Dependent Cell CytotoxicityAntineoplastic AgentsCell Line, TumorIntercellular Signaling Peptides and ProteinsMacaca fascicularisMembrane ProteinsXenograft Model Antitumor Assays

Stichwörter der Autor:innen

CBA-1205Delta-like 1 homologafucosylated antibodyantibody-dependent cellular cytotoxicityhepatocellular carcinoma

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsCalcium-Binding ProteinsDLK1 protein, humanIntercellular Signaling Peptides and ProteinsMembrane Proteins

Autor:innen und Institutionen

  • Chiome Bioscience Inc., 3-12-1 Honmachi, Shibuya-ku, Tokyo 151-0071, Japan.

ORCID-Profile: Koji Nakamura

Zitieren

APA

Nakamura, K., Takahashi, K., Sakaguchi, I., Satoh, T., Zhang, L., Yanai, H., & Tsukumo, Y. (2024). A Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252413627

Vancouver

Nakamura K, Takahashi K, Sakaguchi I, Satoh T, Zhang L, Yanai H, et al. A Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252413627

BibTeX
@article{Nakamura2024,
  author = {Nakamura, Koji and Takahashi, Kota and Sakaguchi, Izumi and Satoh, Takumi and Zhang, Lingyi and Yanai, Hiroyuki and Tsukumo, Yukihito},
  title = {A Novel Glycoengineered Humanized Antibody Targeting DLK1 Exhibits Potent Anti-Tumor Activity in DLK1-Expressing Liver Cancer Cell Xenograft Models},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252413627}
}
Kostenlos starten →